Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 as04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years

Thanyawee Puthanakit, Li Min Huang, Cheng Hsun Chiu, Ren Bin Tang, Tino F. Schwarz, Susanna Esposito, Louise Frenette, Carlo Giaquinto, Shelly McNeil, Paul Rheault, Paolo Durando, Michael Horn, Maximilian Klar, Sylviane Poncelet, Stéphanie De Simoni, Damien Friel, Benoit De Muynck, Pemmaraju V. Suryakiran, Marjan Hezareh, Dominique DescampsFlorence Thomas, Frank Struyf

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background. This randomized, open trial compared regimens including 2 doses (2D) of human papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine in girls aged 9-14 years with one including 3 doses (3D) in women aged 15-25 years. Methods. Girls aged 9-14 years were randomized to receive 2D at months 0 and 6 (M0,6; (n = 550) or months 0 and 12 (M0,12; n = 415), and women aged 15-25 years received 3D at months 0, 1, and 6 (n = 482). End points included noninferiority of HPV-16/ 18 antibodies by enzyme-linked immunosorbent assay for 2D (M0,6) versus 3D (primary), 2D (M0,12) versus 3D, and 2D (M0,6) versus 2D (M0,12); neutralizing antibodies; cell-mediated immunity; reactogenicity; and safety. Limits of noninferiority were predefined as <5% difference in seroconversion rate and <2-fold difference in geometric mean antibody titer ratio. Results. One month after the last dose, both 2D regimens in girls aged 9-14 years were noninferior to 3D in women aged 15-25 years and 2D (M0,12) was noninferior to 2D (M0,6). Geometric mean antibody titer ratios (3D/2D) for HPV-16 and HPV-18 were 1.09 (95% confidence interval, .97-1.22) and 0.85 (.76-.95) for 2D (M0,6) versus 3D and 0.89 (.79-1.01) and 0.75 (.67-.85) for 2D (M0,12) versus 3D. The safety profile was clinically acceptable in all groups. Conclusions. The 2D regimens for the HPV-16/18 AS04-adjuvanted vaccine in girls aged 9-14 years (M0,6 or M0,12) elicited HPV-16/18 immune responses that were noninferior to 3D in women aged 15-25 years.

Original languageEnglish
Pages (from-to)525-536
Number of pages12
JournalJournal of Infectious Diseases
Volume214
Issue number4
DOIs
Publication statusPublished - Aug 15 2016

Fingerprint

Human papillomavirus 18
Human papillomavirus 16
Vaccines
Antibodies
Safety
Neutralizing Antibodies
Cellular Immunity
Enzyme-Linked Immunosorbent Assay
Confidence Intervals

Keywords

  • 2-dose schedule
  • Adjuvant System containing 50 ?g 3-O-desacyl-4?-monophosphoryl lipid A (MPL) adsorbed on aluminum salt (500 ?g Al3+)
  • AS04
  • Cell-mediated immunity
  • Cervical cancer
  • CMI
  • Geometric mean antibody titer
  • GMT
  • HPV
  • Human papillomavirus
  • IgG
  • Immunogenicity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 as04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years. / Puthanakit, Thanyawee; Huang, Li Min; Chiu, Cheng Hsun; Tang, Ren Bin; Schwarz, Tino F.; Esposito, Susanna; Frenette, Louise; Giaquinto, Carlo; McNeil, Shelly; Rheault, Paul; Durando, Paolo; Horn, Michael; Klar, Maximilian; Poncelet, Sylviane; De Simoni, Stéphanie; Friel, Damien; De Muynck, Benoit; Suryakiran, Pemmaraju V.; Hezareh, Marjan; Descamps, Dominique; Thomas, Florence; Struyf, Frank.

In: Journal of Infectious Diseases, Vol. 214, No. 4, 15.08.2016, p. 525-536.

Research output: Contribution to journalArticle

Puthanakit, T, Huang, LM, Chiu, CH, Tang, RB, Schwarz, TF, Esposito, S, Frenette, L, Giaquinto, C, McNeil, S, Rheault, P, Durando, P, Horn, M, Klar, M, Poncelet, S, De Simoni, S, Friel, D, De Muynck, B, Suryakiran, PV, Hezareh, M, Descamps, D, Thomas, F & Struyf, F 2016, 'Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 as04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years', Journal of Infectious Diseases, vol. 214, no. 4, pp. 525-536. https://doi.org/10.1093/infdis/jiw036
Puthanakit, Thanyawee ; Huang, Li Min ; Chiu, Cheng Hsun ; Tang, Ren Bin ; Schwarz, Tino F. ; Esposito, Susanna ; Frenette, Louise ; Giaquinto, Carlo ; McNeil, Shelly ; Rheault, Paul ; Durando, Paolo ; Horn, Michael ; Klar, Maximilian ; Poncelet, Sylviane ; De Simoni, Stéphanie ; Friel, Damien ; De Muynck, Benoit ; Suryakiran, Pemmaraju V. ; Hezareh, Marjan ; Descamps, Dominique ; Thomas, Florence ; Struyf, Frank. / Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 as04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years. In: Journal of Infectious Diseases. 2016 ; Vol. 214, No. 4. pp. 525-536.
@article{b76c83c7e3ee480cb64580e3c27f873b,
title = "Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 as04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years",
abstract = "Background. This randomized, open trial compared regimens including 2 doses (2D) of human papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine in girls aged 9-14 years with one including 3 doses (3D) in women aged 15-25 years. Methods. Girls aged 9-14 years were randomized to receive 2D at months 0 and 6 (M0,6; (n = 550) or months 0 and 12 (M0,12; n = 415), and women aged 15-25 years received 3D at months 0, 1, and 6 (n = 482). End points included noninferiority of HPV-16/ 18 antibodies by enzyme-linked immunosorbent assay for 2D (M0,6) versus 3D (primary), 2D (M0,12) versus 3D, and 2D (M0,6) versus 2D (M0,12); neutralizing antibodies; cell-mediated immunity; reactogenicity; and safety. Limits of noninferiority were predefined as <5{\%} difference in seroconversion rate and <2-fold difference in geometric mean antibody titer ratio. Results. One month after the last dose, both 2D regimens in girls aged 9-14 years were noninferior to 3D in women aged 15-25 years and 2D (M0,12) was noninferior to 2D (M0,6). Geometric mean antibody titer ratios (3D/2D) for HPV-16 and HPV-18 were 1.09 (95{\%} confidence interval, .97-1.22) and 0.85 (.76-.95) for 2D (M0,6) versus 3D and 0.89 (.79-1.01) and 0.75 (.67-.85) for 2D (M0,12) versus 3D. The safety profile was clinically acceptable in all groups. Conclusions. The 2D regimens for the HPV-16/18 AS04-adjuvanted vaccine in girls aged 9-14 years (M0,6 or M0,12) elicited HPV-16/18 immune responses that were noninferior to 3D in women aged 15-25 years.",
keywords = "2-dose schedule, Adjuvant System containing 50 ?g 3-O-desacyl-4?-monophosphoryl lipid A (MPL) adsorbed on aluminum salt (500 ?g Al3+), AS04, Cell-mediated immunity, Cervical cancer, CMI, Geometric mean antibody titer, GMT, HPV, Human papillomavirus, IgG, Immunogenicity",
author = "Thanyawee Puthanakit and Huang, {Li Min} and Chiu, {Cheng Hsun} and Tang, {Ren Bin} and Schwarz, {Tino F.} and Susanna Esposito and Louise Frenette and Carlo Giaquinto and Shelly McNeil and Paul Rheault and Paolo Durando and Michael Horn and Maximilian Klar and Sylviane Poncelet and {De Simoni}, St{\'e}phanie and Damien Friel and {De Muynck}, Benoit and Suryakiran, {Pemmaraju V.} and Marjan Hezareh and Dominique Descamps and Florence Thomas and Frank Struyf",
year = "2016",
month = "8",
day = "15",
doi = "10.1093/infdis/jiw036",
language = "English",
volume = "214",
pages = "525--536",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 as04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years

AU - Puthanakit, Thanyawee

AU - Huang, Li Min

AU - Chiu, Cheng Hsun

AU - Tang, Ren Bin

AU - Schwarz, Tino F.

AU - Esposito, Susanna

AU - Frenette, Louise

AU - Giaquinto, Carlo

AU - McNeil, Shelly

AU - Rheault, Paul

AU - Durando, Paolo

AU - Horn, Michael

AU - Klar, Maximilian

AU - Poncelet, Sylviane

AU - De Simoni, Stéphanie

AU - Friel, Damien

AU - De Muynck, Benoit

AU - Suryakiran, Pemmaraju V.

AU - Hezareh, Marjan

AU - Descamps, Dominique

AU - Thomas, Florence

AU - Struyf, Frank

PY - 2016/8/15

Y1 - 2016/8/15

N2 - Background. This randomized, open trial compared regimens including 2 doses (2D) of human papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine in girls aged 9-14 years with one including 3 doses (3D) in women aged 15-25 years. Methods. Girls aged 9-14 years were randomized to receive 2D at months 0 and 6 (M0,6; (n = 550) or months 0 and 12 (M0,12; n = 415), and women aged 15-25 years received 3D at months 0, 1, and 6 (n = 482). End points included noninferiority of HPV-16/ 18 antibodies by enzyme-linked immunosorbent assay for 2D (M0,6) versus 3D (primary), 2D (M0,12) versus 3D, and 2D (M0,6) versus 2D (M0,12); neutralizing antibodies; cell-mediated immunity; reactogenicity; and safety. Limits of noninferiority were predefined as <5% difference in seroconversion rate and <2-fold difference in geometric mean antibody titer ratio. Results. One month after the last dose, both 2D regimens in girls aged 9-14 years were noninferior to 3D in women aged 15-25 years and 2D (M0,12) was noninferior to 2D (M0,6). Geometric mean antibody titer ratios (3D/2D) for HPV-16 and HPV-18 were 1.09 (95% confidence interval, .97-1.22) and 0.85 (.76-.95) for 2D (M0,6) versus 3D and 0.89 (.79-1.01) and 0.75 (.67-.85) for 2D (M0,12) versus 3D. The safety profile was clinically acceptable in all groups. Conclusions. The 2D regimens for the HPV-16/18 AS04-adjuvanted vaccine in girls aged 9-14 years (M0,6 or M0,12) elicited HPV-16/18 immune responses that were noninferior to 3D in women aged 15-25 years.

AB - Background. This randomized, open trial compared regimens including 2 doses (2D) of human papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine in girls aged 9-14 years with one including 3 doses (3D) in women aged 15-25 years. Methods. Girls aged 9-14 years were randomized to receive 2D at months 0 and 6 (M0,6; (n = 550) or months 0 and 12 (M0,12; n = 415), and women aged 15-25 years received 3D at months 0, 1, and 6 (n = 482). End points included noninferiority of HPV-16/ 18 antibodies by enzyme-linked immunosorbent assay for 2D (M0,6) versus 3D (primary), 2D (M0,12) versus 3D, and 2D (M0,6) versus 2D (M0,12); neutralizing antibodies; cell-mediated immunity; reactogenicity; and safety. Limits of noninferiority were predefined as <5% difference in seroconversion rate and <2-fold difference in geometric mean antibody titer ratio. Results. One month after the last dose, both 2D regimens in girls aged 9-14 years were noninferior to 3D in women aged 15-25 years and 2D (M0,12) was noninferior to 2D (M0,6). Geometric mean antibody titer ratios (3D/2D) for HPV-16 and HPV-18 were 1.09 (95% confidence interval, .97-1.22) and 0.85 (.76-.95) for 2D (M0,6) versus 3D and 0.89 (.79-1.01) and 0.75 (.67-.85) for 2D (M0,12) versus 3D. The safety profile was clinically acceptable in all groups. Conclusions. The 2D regimens for the HPV-16/18 AS04-adjuvanted vaccine in girls aged 9-14 years (M0,6 or M0,12) elicited HPV-16/18 immune responses that were noninferior to 3D in women aged 15-25 years.

KW - 2-dose schedule

KW - Adjuvant System containing 50 ?g 3-O-desacyl-4?-monophosphoryl lipid A (MPL) adsorbed on aluminum salt (500 ?g Al3+)

KW - AS04

KW - Cell-mediated immunity

KW - Cervical cancer

KW - CMI

KW - Geometric mean antibody titer

KW - GMT

KW - HPV

KW - Human papillomavirus

KW - IgG

KW - Immunogenicity

UR - http://www.scopus.com/inward/record.url?scp=84988975003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988975003&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiw036

DO - 10.1093/infdis/jiw036

M3 - Article

AN - SCOPUS:84988975003

VL - 214

SP - 525

EP - 536

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -